Understanding the key features of the spontaneous formation of bona fide prions through a novel methodology that enables their swift and consistent generation.

"Declarations Competing interestsAuthors have read the journal’s policy and have the following competing interests that need to be declared: Authors Hasier Eraña and Jorge M. Charco are employed by the commercial company ATLAS Molecular Pharma SL. This does not alter our adherence to all Journal policies on sharing data and materials and did not influence in any way the work reported in this manuscript. Competing interests Authors have read the journal’s policy and have the following competing interests that need to be declared: Authors Hasier Eraña and Jorge M. Charco are employed by the commercial company ATLAS Molecular Pharma SL. This does not alter our adherence to all Journal policies on sharing data and materials and did not influence in any way the work reported in this manuscript."

"Funding The present work was partially funded by three different grants awarded by “Ministerio de Economía y Competitividad” (Spanish Government), grant numbers PID2021-122201OB-C21, PID2021-1222010B-C22 and PID2020-117465GB-I00, funded by MCIN/AEI/10.13039/501100011033 and co-financed by the European Regional Development Fund (ERDF), and by the Instituto de Salud Carlos III (ISCIII), grant number AC21_2/00024. Additionally, CIC bioGUNE currently holds a Severo Ochoa Excellence accreditation, CEX2021-001136-S, also funded by MCIN/AEI/10.13039/501100011033. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."